公开(公告)号：US20230381237A1

公开(公告)日：2023-11-30

申请号：US18325930

申请日：2023-05-30

申请人： CytoAgents, Inc.

发明人： Jodi CRAIGO ,  Teresa WHALEN ,  Heather Lynn NOTTINGHAM ,  Arthur P. BERTOLINO

IPC分类号： A61K35/17 ,  A61K31/5585 ,  A61P35/00 ,  A61K9/00

CPC分类号： A61K35/17 ,  A61K31/5585 ,  A61P35/00 ,  A61K9/0019

摘要： Methods, compositions, and kits that can be used to treat cytokine release syndrome, ICANS, or both, associated with CAR T-cell administration are described herein. For example, pharmaceutical compositions containing beraprost, beraprost isomers, or salts thereof can be used as an adjuvant therapy with chimeric antigen receptor T cells (CAR T-cells) to treat cancer while reducing or eliminating undesired and potentially dangerous side effects.

公开(公告)号：US20230255892A1

公开(公告)日：2023-08-17

申请号：US17991697

申请日：2022-11-21

申请人： Supernus Pharmaceuticals, Inc.

发明人： Argaw Kidane ,  Padmanabh P Bhatt

IPC分类号： A61K9/28 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585 ,  A61K31/192

CPC分类号： A61K9/282 ,  A61K9/0004 ,  A61K9/28 ,  A61K9/286 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/2013 ,  A61K9/2077 ,  A61K9/2826 ,  A61K31/192 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585

摘要： An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.

公开(公告)号：US11666615B2

公开(公告)日：2023-06-06

申请号：US16783717

申请日：2020-02-06

申请人： Tadashi Tanabe ,  Keiichi Hukuda ,  Takashi Kawakami

发明人： Tadashi Tanabe ,  Keiichi Hukuda ,  Takashi Kawakami

IPC分类号： A61K35/76 ,  A61K31/5585 ,  A61K38/18 ,  A61K38/52 ,  A61K45/06 ,  A61K48/00 ,  C12N7/00 ,  A61K35/13

CPC分类号： A61K35/76 ,  A61K31/5585 ,  A61K38/1825 ,  A61K38/1833 ,  A61K38/1866 ,  A61K38/52 ,  A61K45/06 ,  A61K48/005 ,  C12N7/00 ,  C12Y503/99004 ,  A61K35/13 ,  C12N2750/14132 ,  C12N2750/14143 ,  C12N2799/025 ,  A61K38/1866 ,  A61K2300/00 ,  A61K38/1825 ,  A61K2300/00 ,  A61K38/1833 ,  A61K2300/00 ,  A61K38/52 ,  A61K2300/00

摘要： The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF). The method includes administering, to an individual, a composition including adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin I2 (PGI2).

公开(公告)号：US11666602B2

公开(公告)日：2023-06-06

申请号：US16124532

申请日：2018-09-07

申请人： United Therapeutics Corporation

发明人： Roger Jeffs ,  Thomas Petersen ,  Roger M. Ilagan ,  Michael Wade

IPC分类号： A61K31/192 ,  A61K35/28 ,  A61K35/44 ,  A61K45/06 ,  C12N5/0775 ,  A61K31/5585 ,  C12N5/071 ,  A61K48/00 ,  A61K35/12

CPC分类号： A61K35/28 ,  A61K31/192 ,  A61K31/5585 ,  A61K35/44 ,  A61K45/06 ,  C12N5/0663 ,  C12N5/0692 ,  A61K48/005 ,  A61K2035/124 ,  C12N2501/02 ,  A61K31/5585 ,  A61K2300/00 ,  A61K35/28 ,  A61K2300/00

摘要： The application is directed to a method for treating or preventing vasculopathy comprising administrating to a subject in need thereof a pharmaceutical composition comprising mesenchymal precursor cells (MPCs) and a prostacyclin. Also provided a method for treating or preventing vasculopathy in a subject in need thereof, comprising administering to the subject a prostacyclin and a mesenchymal stem cell (MSC) or a MSC-conditioned culture medium or administering to the subject a MSC or a MSC-conditioned culture medium that has treated with prostacyclin. Pharmaceutical compositions suitable for such treatments are also provided.

公开(公告)号：US20230022200A1

公开(公告)日：2023-01-26

申请号：US17781778

申请日：2020-12-23

申请人： Toray Industries, Inc.

发明人： Hajimu Kurumatani ,  Kiyonobu Okada ,  Naohiro Yamada ,  Takashi Kiriyama ,  Hiroyuki Kano ,  Shunsuke Yamada

IPC分类号： A61K31/5585 ,  A61P13/12 ,  A61K9/20

摘要： A method of preventing dialysis shift or renal death includes administering to a primary glomerular disease or nephrosclerosis patient with a serum creatinine level of 2.0 mg/dl or more and less than 3.0 mg/dl a sustained-release preparation including, as an active ingredient, a compound represented by formula (I): wherein R represents hydrogen or a pharmacologically acceptable cation, such that the compound represented by formula (I) is administered at 220 to 260 μg per day.

公开(公告)号：US20200171109A1

公开(公告)日：2020-06-04

申请号：US16783717

申请日：2020-02-06

申请人： Tadashi Tanabe ,  Keiichi Hukuda ,  Takashi Kawakami

发明人： Tadashi Tanabe ,  Keiichi Hukuda ,  Takashi Kawakami

IPC分类号： A61K35/76 ,  A61K31/5585 ,  A61K38/18 ,  A61K38/52 ,  A61K45/06 ,  A61K48/00 ,  C12N7/00

摘要： The present invention relates to a method for inducing production of vascular endothelial growth factor (VEGF). The method includes administering, to an individual, a composition including adeno-associated virus (AAV) carrying a hPGIS gene coding for human prostacyclin synthase (hPGIS) which synthesizes prostaglandin I2 (PGI2).

公开(公告)号：US10149909B2

公开(公告)日：2018-12-11

申请号：US15371277

申请日：2016-12-07

申请人： Toray Industries, Inc.

发明人： Hajimu Kurumatani ,  Mitsutaka Tamura

IPC分类号： A61K31/343 ,  A61K47/22 ,  A61K31/4184 ,  A61K31/5585 ,  A61K45/06 ,  C07D307/93 ,  A61K31/401 ,  A61K31/404 ,  A61K31/4178 ,  A61K31/403

摘要： An agent enhances the therapeutic or prophylactic effect of a renin-angiotensin system inhibitor on renal diseases, including a specific prostaglandin I derivative such as beraprost sodium as an effective ingredient.

公开(公告)号：US20180246123A9

公开(公告)日：2018-08-30

申请号：US15562259

申请日：2016-03-22

申请人： Sisse Rye OSTROWSKI ,  Pär Ingemar JOHANSSON

发明人： Sisse Rye OSTROWSKI ,  Pär Ingemar JOHANSSON

IPC分类号： G01N33/68 ,  G01N33/58 ,  A61K31/5585 ,  A61K45/06

CPC分类号： G01N33/6893 ,  A61K31/5585 ,  A61K45/06 ,  A61K2300/00 ,  G01N33/58 ,  G01N33/68

摘要： Use of prostacyclin or an analogue thereof for treatment of a new medical indication in acute critically ill patients, in particular acute critically ill patients with systemic endothelial damage, a biomarker for identifying individuals that have a new medical indication, and a method for identifying a new medical indication.

公开(公告)号：US09566245B2

公开(公告)日：2017-02-14

申请号：US15162829

申请日：2016-05-24

申请人： Supernus Pharmaceuticals, Inc.

发明人： Argaw Kidane ,  Padmanabh P Bhatt

IPC分类号： A61K9/24 ,  A61K9/28 ,  A61K9/00 ,  A61K9/16 ,  A61K9/20 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/5585 ,  A61K31/192

摘要： An oral osmotic pharmaceutical delivery system comprises a highly water-soluble drug exhibiting an erratic or an incomplete release profile when formulated in an elementary osmotic pump delivery system and at least one release enhancing agent.

公开(公告)号：US09504695B2

公开(公告)日：2016-11-29

申请号：US14509680

申请日：2014-10-08

申请人： Topokine Therapeutics, Inc.

发明人： Murat V. Kalayoglu

IPC分类号： A61K31/5575 ,  C07C405/00 ,  A61P3/04 ,  A61K31/5585 ,  C07C69/732 ,  C07C235/30 ,  C07D307/20 ,  A61K31/133

CPC分类号： A61K31/5575 ,  A61K9/0014 ,  A61K31/133 ,  A61K31/5585 ,  C07C69/732 ,  C07C235/30 ,  C07D307/20

摘要： Provided are methods, compositions, systems, and kits for treating metabolic syndrome or a disorder associated with metabolic syndrome, e.g., obesity, dyslipidemia, and/or a diabetic condition, comprising administering systemically to a subject one or more compounds of the Formula (I) and/or (II): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, polymorph, tautomer, isotopically enriched derivative, or prodrug thereof, wherein , L, R1, R2, Z, X, A and B are defined herein.